Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An externally validated machine learning algorithm for predicting mental and physical health outcomes three months post-hospitalization for severe viral infection with SARS-CoV-2.

Brain, behavior, & immunity - health·2026
Same author

Dynamic remodeling of portal vessels by Clec4g+ endothelial cells in liver growth and homeostasis.

JCI insight·2026
Same author

Liver Disease Reveals KIF12 as a Critical Regulator of Mitochondria, Lysosome and Cilia Localization.

bioRxiv : the preprint server for biology·2026
Same author

Challenges in the diagnosis and treatment of genetic cholestasis in adults.

JHEP reports : innovation in hepatology·2026
Same author

Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.

Cancer cell·2026
Same author

Prevalence and Impact on Quality of Life of Small Intestinal Bacterial Overgrowth (SIBO)-Related Symptoms in Patients with Upper Gastrointestinal Cancer.

Diseases (Basel, Switzerland)·2025
Same journal

Reply to "Comparison of patients with HBV-related HCC with and without MASLD after liver transplantation".

JHEP reports : innovation in hepatology·2026
Same journal

Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy.

JHEP reports : innovation in hepatology·2026
Same journal

Sexual dimorphism in the association of circulating TAM receptors-ligands with MASLD-related fibrosis.

JHEP reports : innovation in hepatology·2026
Same journal

Aiming at a Moving Target: ReMELD-Na Before and After Portal Decompression.

JHEP reports : innovation in hepatology·2026
Same journal

Longitudinal GGT Trajectories Identify Prognostic Phenotypes in Paediatric Primary Sclerosing Cholangitis.

JHEP reports : innovation in hepatology·2026
Same journal

Global Trends in National Alcohol Control Policies Between 2010-2019.

JHEP reports : innovation in hepatology·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Genetic Testing in Liver Diseases: Clinical Applications.

Verena Keitel1, Anne Mentzinger2, Carola Dröge1

  • 1Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg Otto von Guericke University, Magdeburg, Germany.

JHEP Reports : Innovation in Hepatology
|May 29, 2026
PubMed
Summary
This summary is machine-generated.

Genomic testing is increasingly vital for diagnosing and managing adult liver diseases. This review highlights its expanding role in hepatology, offering clinical insights and emphasizing specialized genomic expertise.

Keywords:
Human genetics and genomicsgene panelsinherited liver diseasesunexplained liver diseasewhole-exome sequencing

More Related Videos

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Related Experiment Videos

Last Updated: May 31, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Area of Science:

  • Genomic Medicine
  • Hepatology
  • Clinical Genetics

Background:

  • Human genetics is key to understanding disease mechanisms.
  • Advances in genomic technology have lowered costs and improved data quality.
  • Genomic medicine adoption is expanding beyond pediatrics, neurology, and oncology into adult hepatology.

Purpose of the Study:

  • To review the evidence for genetic testing in adult liver diseases.
  • To provide actionable insights for clinical practice in hepatology.
  • To discuss the future of genomic hepatology and its impact on training and practice.

Main Methods:

  • Literature review synthesizing evidence on genetic testing in liver diseases.
  • Focus on specific conditions: cholestatic disorders, hepatic steatosis, cirrhosis, portal hypertension, and acute liver failure.
  • Discussion of the role of specialized centers and multidisciplinary teams.

Main Results:

  • Genetic testing is increasingly valuable for diagnosing and managing a spectrum of adult liver diseases.
  • High-yield learning points and clinical insights are derived from current evidence.
  • Specialized centers and genomic hepatology expertise are crucial for effective implementation.

Conclusions:

  • The application of genomic medicine in adult hepatology is rapidly growing.
  • Genetic testing offers significant potential for improving patient diagnosis and management in liver disease.
  • An integrated genomic ecosystem is essential for the future of clinical hepatology.